Homepage Top Section1

The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have

ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase

The investment round saw contributions from Gimv, HealthCap, Red Tree Venture Capital, and existing backers BioGeneration Ventures, M Ventures, and Brabantse Ontwikkelings Maatschappij (BOM). The funds will be

The CRL, dated 22 October 2024, comes ahead of the Generic Drug User Fee Amendments of 2022 (GDUFA) goal date set for 29 October 2024. Ketamine, an essential

The acquisition bolsters AscellaHealth’s capabilities to serve international manufacturers and patients in more than 70 countries across the EU, Asia, Africa, Australia and the Americas. CHAPPER healthcare is

The contract, with a maximum value of $80m over a five-year period, is part of the NIH’s Helping to End Addiction Long-term Initiative (HEAL Initiative) and falls under

This move aims to bolster AstraZeneca’s cardiovascular portfolio in addressing key risk factors associated with chronic cardiovascular diseases. As per the agreement terms, AstraZeneca will gain access to

With the latest development, Otulfi is now intended to treat Crohn’s disease, moderate to severe plaque psoriasis, ulcerative colitis and active psoriatic arthritis. Fresenius Kabi and Formycon signed

The product is the result of a collaboration with the Agency for Science, Technology, and Research (A*STAR), featuring patented active pH control technology to address the skin condition.